摘要
目的:观察尼可地尔对急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后炎性因子及脑钠肽(BNP)的影响。方法:将128例行择期PCI治疗的ACS住院患者随机分为治疗组(70例)和对照组(58例)。对照组进行常规治疗,治疗组在常规治疗基础上,在手术前24h开始服用尼可地尔(5mg,tid)。检测两组手术前、术后2h、术后1d及术后3d的高敏C-反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)及BNP的浓度。结果:两组PCI术后2h的血清hs-CRP、MMP-9及BNP浓度均较术前升高(均P<0.01),但两组间比较差异无统计学意义。治疗组术后第1天及第3天hs-CRP及BNP较对照组明显下降(均P<0.01)。结论:口服尼可地尔可降低ACS患者PCI后第1天和第3天的血浆hs-CRP和BNP浓度。
Objective：To observe the effects of nicorandil on plasma inflammatory factor and brain natriuretic peptide （BNP） in patients with acute coronary syndrome （ACS） after pereutaneous coronary intervention （PCI）. Method：A total of 128 hospitalized patients with ACS were randomly divided into treatment group （70 eases） and control group （58 cases）. AlJ patients underwent elective PCI. The control group was given conventional therapy. Exception of conventional therapy, the treatment group took nieorandil （5 mg Tid） 24 hours before PCI. The concentration of plasma bs-CRP, MMP 9 and BNP were examined at 2 hours, 1 day and 3 days post-- PCI. Result： The concentration of plasma hs-CRP, MMP-9 and BNP in the both groups were increased after PCI （both P〈 0.05）. At 1 day and 3 days after PCI, plasma hs CRP and BNP in treatment group were reduced compared with control （both P〈0.05）. Conclusion： Nicorandil can reduce the plasma concentration of hs-CRP and BNP in patients with ACS after PCI.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2013年第7期503-505,共3页
Journal of Clinical Cardiology
基金
广西区卫生厅自筹经费科研课题(计划课题)
